0001830487Q22025false--12-312025-06-3000018304872023-12-310001830487phvs:RestrictedStockUnitsMember2024-12-310001830487ifrs-full:GrossCarryingAmountMember2025-06-300001830487ifrs-full:IssuedCapitalMember2025-06-300001830487phvs:ClinicalExpensesMember2025-01-012025-06-300001830487ifrs-full:KeyManagementPersonnelOfEntityOrParentMember2024-01-012024-06-300001830487country:US2024-12-310001830487phvs:PersonnelExpensesMember2024-01-012024-06-300001830487ifrs-full:KeyManagementPersonnelOfEntityOrParentMemberphvs:BlackScholesFormulaMember2025-03-122025-03-120001830487ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-12-310001830487ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2023-12-310001830487phvs:PersonnelRelatedAccrualsMember2025-06-300001830487ifrs-full:AccumulatedDepreciationAndAmortisationMember2025-01-012025-06-300001830487ifrs-full:KeyManagementPersonnelOfEntityOrParentMember2025-01-012025-06-3000018304872025-04-012025-04-010001830487phvs:PharvarisIncMember2024-01-012024-06-300001830487phvs:StockOptionsMember2024-12-310001830487ifrs-full:GrossCarryingAmountMember2023-12-310001830487country:US2025-06-300001830487phvs:MoneyMarketFundMemberifrs-full:AtCostMember2024-12-310001830487phvs:ConsultingProfessionalAndAuditLiabilityMember2024-12-310001830487phvs:MorganStanleyCoLlcAndLeerinkPartnersLlcMemberphvs:PreFundedWarrantsMember2023-12-310001830487phvs:PersonnelExpensesMember2025-04-012025-06-300001830487ifrs-full:SharePremiumMember2025-06-300001830487phvs:RestrictedStockUnitsMemberifrs-full:KeyManagementPersonnelOfEntityOrParentMember2025-01-012025-06-300001830487phvs:StockOptionsMember2025-06-300001830487phvs:OfficeLeaseMember2024-12-310001830487phvs:LicenseCostsMember2025-01-012025-06-300001830487ifrs-full:SharePremiumMember2024-06-300001830487phvs:LicenseCostsMember2025-04-012025-06-300001830487phvs:LicenseCostsMember2024-01-012024-06-3000018304872025-02-012025-02-010001830487ifrs-full:IssuedCapitalMember2023-12-310001830487phvs:NonclinicalExpensesMember2024-04-012024-06-300001830487phvs:PharvarisHoldingsBvMember2025-01-012025-06-300001830487ifrs-full:SharePremiumMember2024-12-3100018304872025-03-012025-03-010001830487ifrs-full:AccumulatedDepreciationAndAmortisationMember2023-12-310001830487ifrs-full:OrdinarySharesMember2025-06-300001830487phvs:StockOptionsGrantedToBoardOfDirectorsMemberphvs:BlackScholesFormulaMember2025-03-120001830487phvs:IntellectualPropertyCostsMember2025-01-012025-06-3000018304872025-01-012025-06-300001830487ifrs-full:KeyManagementPersonnelOfEntityOrParentMemberphvs:BlackScholesFormulaMember2025-03-120001830487phvs:NonclinicalAccruedLiabilitiesMember2024-12-310001830487phvs:ClinicalExpensesMember2025-04-012025-06-300001830487phvs:PharvarisHoldingsBvMember2024-01-012024-06-300001830487ifrs-full:SharePremiumMember2023-12-3100018304872025-06-300001830487phvs:ManufacturingCostsMember2025-01-012025-06-300001830487phvs:ManufacturingCostsMember2024-01-012024-06-300001830487ifrs-full:AccumulatedDepreciationAndAmortisationMember2024-12-310001830487ifrs-full:KeyManagementPersonnelOfEntityOrParentMember2024-12-3100018304872025-05-012025-05-010001830487phvs:LicenseCostsMember2024-04-012024-06-300001830487ifrs-full:KeyManagementPersonnelOfEntityOrParentMember2025-03-122025-03-120001830487phvs:RestrictedStockUnitsMember2025-06-300001830487phvs:PersonnelExpensesMember2024-04-012024-06-3000018304872024-01-012024-12-310001830487phvs:PersonnelRelatedAccrualsMember2024-12-3100018304872023-01-012023-06-300001830487ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-06-300001830487ifrs-full:SharePremiumMember2024-01-012024-06-300001830487ifrs-full:IssuedCapitalMember2024-12-310001830487phvs:LeerinkPartnersMember2024-04-012024-04-300001830487phvs:OtherAccruedLiabilitiesMember2025-06-300001830487ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2025-06-3000018304872023-06-300001830487ifrs-full:OrdinarySharesMember2025-01-012025-06-300001830487phvs:NonclinicalExpensesMember2024-01-012024-06-3000018304872024-01-012024-06-300001830487ifrs-full:IssuedCapitalMember2024-06-300001830487ifrs-full:KeyManagementPersonnelOfEntityOrParentMemberphvs:ExercisePriceOfEUR1474PerShareMember2025-03-122025-03-120001830487phvs:PharvarisGmbhMember2024-01-012024-06-300001830487ifrs-full:KeyManagementPersonnelOfEntityOrParentMember2025-06-300001830487phvs:ManufacturingCostsMember2025-04-012025-06-300001830487ifrs-full:GrossCarryingAmountMember2024-12-310001830487ifrs-full:RetainedEarningsMember2024-01-012024-06-300001830487phvs:NonclinicalAccruedLiabilitiesMember2025-06-300001830487phvs:ClinicalAccruedLiabilitiesMember2025-06-3000018304872024-01-012024-01-310001830487phvs:LeerinkPartnersMember2025-01-012025-06-300001830487phvs:PharvarisPharmaceuticalsIncMember2025-01-012025-06-300001830487phvs:StockOptionsGrantedToBoardOfDirectorsMemberphvs:BlackScholesFormulaMember2025-03-122025-03-120001830487phvs:PharvarisNetherlandsBvMember2025-01-012025-06-3000018304872024-04-012024-06-300001830487phvs:RestrictedStockUnitsMemberphvs:StockOptionsGrantedToBoardOfDirectorsMember2025-01-012025-06-300001830487phvs:RestrictedStockUnitsMemberphvs:EmployeesMember2025-01-012025-06-300001830487phvs:PharvarisIncMember2025-01-012025-06-300001830487phvs:PersonnelExpensesMember2025-01-012025-06-300001830487phvs:IntellectualPropertyCostsMember2025-04-012025-06-300001830487phvs:MorganStanleyCoLlcAndLeerinkPartnersLlcMember2023-01-012023-12-310001830487ifrs-full:IssuedCapitalMember2025-01-012025-06-300001830487ifrs-full:RetainedEarningsMember2024-12-310001830487phvs:NonclinicalExpensesMember2025-01-012025-06-300001830487ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2025-01-012025-06-300001830487phvs:MorganStanleyCoLlcAndLeerinkPartnersLlcMember2023-12-310001830487ifrs-full:GrossCarryingAmountMember2024-01-012024-12-310001830487ifrs-full:AccumulatedDepreciationAndAmortisationMember2024-01-012024-12-310001830487ifrs-full:RetainedEarningsMember2024-06-300001830487phvs:MorganStanleyCoLlcAndLeerinkPartnersLlcMemberifrs-full:OrdinarySharesMember2023-12-310001830487phvs:OtherAccruedLiabilitiesMember2024-12-3100018304872025-03-122025-03-1200018304872022-01-012022-03-310001830487ifrs-full:RetainedEarningsMember2025-06-300001830487ifrs-full:SharePremiumMember2025-01-012025-06-300001830487phvs:OfficeLeaseMember2025-06-3000018304872025-04-012025-06-300001830487phvs:MoneyMarketFundMemberifrs-full:AtCostMember2025-06-300001830487ifrs-full:AccumulatedDepreciationAndAmortisationMember2025-06-300001830487ifrs-full:OtherReservesMember2023-12-310001830487phvs:StockOptionsGrantedToBoardOfDirectorsMemberphvs:ShareOptionsVestingMember2025-03-122025-03-120001830487phvs:IntellectualPropertyCostsMember2024-04-012024-06-300001830487phvs:PharvarisGmbhMember2025-01-012025-06-300001830487ifrs-full:IssuedCapitalMember2024-01-012024-06-300001830487phvs:StockOptionsGrantedToBoardOfDirectorsMemberphvs:ExercisePriceOfEUR1474PerShareMember2025-03-122025-03-120001830487ifrs-full:GrossCarryingAmountMember2025-01-012025-06-300001830487ifrs-full:OtherReservesMember2024-12-310001830487phvs:StockOptionsGrantedToBoardOfDirectorsMember2025-03-122025-03-120001830487phvs:ClinicalExpensesMember2024-04-012024-06-300001830487phvs:NonclinicalExpensesMember2025-04-012025-06-300001830487phvs:PharvarisNetherlandsBvMember2024-01-012024-06-300001830487ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-01-012024-06-300001830487phvs:SVBLeerinkMemberifrs-full:OrdinarySharesMember2022-01-012022-03-310001830487ifrs-full:RetainedEarningsMember2025-01-012025-06-300001830487ifrs-full:RetainedEarningsMember2023-12-3100018304872024-12-310001830487phvs:ShareOptionsVestingMember2025-03-122025-03-1200018304872022-01-012022-06-300001830487ifrs-full:OtherReservesMember2024-01-012024-06-300001830487ifrs-full:OtherReservesMember2025-06-300001830487phvs:RestrictedStockUnitsMember2025-01-012025-06-300001830487ifrs-full:OrdinarySharesMember2023-01-012023-06-300001830487phvs:ClinicalAccruedLiabilitiesMember2024-12-310001830487phvs:ClinicalExpensesMember2024-01-012024-06-300001830487phvs:ConsultingProfessionalAndAuditLiabilityMember2025-06-300001830487ifrs-full:OtherReservesMember2025-01-012025-06-300001830487ifrs-full:OtherReservesMember2024-06-300001830487phvs:ManufacturingAccruedLiabilitiesMember2025-06-300001830487phvs:StockOptionsMember2025-01-012025-06-3000018304872024-06-300001830487ifrs-full:OrdinarySharesMember2024-12-310001830487phvs:ManufacturingAccruedLiabilitiesMember2024-12-310001830487phvs:IntellectualPropertyCostsMember2024-01-012024-06-300001830487phvs:MoneyMarketFundMemberifrs-full:AtFairValueMember2025-06-300001830487phvs:ManufacturingCostsMember2024-04-012024-06-30iso4217:EURxbrli:pureiso4217:USDxbrli:sharesxbrli:sharesiso4217:EURxbrli:sharesiso4217:USDutr:Yphvs:Staff

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~Washington~~WASHINGTON, D.C. 20549

FORM 6-K

~~Report~~REPORT ofOF ~~Foreign~~FOREIGN ~~Private~~PRIVATE ~~Issuer~~ISSUERPURSUANT TO RULE 13A-16 OR 15D-16 UNDERTHE SECURITIES EXCHANGE ACT OF 1934

~~Pursuant~~For tothe ~~Rule~~month ~~13a-16~~of orAugust ~~15d-16~~2025Commission File Number: 001-40010

of the Securities Exchange Act of 1934

For the month of July, 2025

Commission File Number: 001-40010

Pharvaris N.V.

(Translation of registrant’s name into English)

Emmy Noetherweg 2

2333 BK Leiden

The Netherlands(Address of principal executive office)

~~(Address~~Indicate by check mark whether the registrant files or will file annual reports under cover of ~~principal~~Form ~~executive~~20-F ~~offices)~~or Form 40-F.

~~Indicate by check mark whether the registrant files or will file annual reports under cover of~~ Form 20-F or ☒ Form 40-F ☐

☒ Form 20-F ☐ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

PHARVARIS N.V.

On ~~July~~August 2212, 2025, Pharvaris N.V. ~~(the~~issued ~~“Company”)~~a ~~entered~~press ~~into~~release anreporting ~~underwriting~~financial ~~agreement~~results (and other business updates for the ~~“Underwriting~~three ~~Agreement”)~~and ~~with~~six ~~Morgan Stanley &~~months Coended June 30, 2025. ~~LLC~~A ~~and~~copy ~~Leerink~~of ~~Partners~~the ~~LLC~~press release is attached hereto as ~~representatives~~Exhibit 99.1 and shall not be deemed “filed” for purposes of Section 18 of the ~~underwriters~~Securities ~~named~~Exchange ~~therein~~Act of 1934 (the “~~Underwriters~~Exchange Act”), ~~pursuant~~or tootherwise ~~which~~subject to the ~~Company~~liabilities ~~agreed~~of tothat ~~issue~~section, ~~and~~nor ~~sell~~shall ~~(i)~~it ~~9,562,500~~be ~~ordinary~~deemed ~~shares,~~incorporated ~~par~~by ~~value~~reference ~~€0.12~~in ~~per share~~any ~~(which~~filing ~~includes~~under the ~~exercise~~Securities inAct ~~full~~of by1933, as amended or the ~~underwriters~~Exchange ofAct. ~~their~~Exhibits ~~option~~99.2 and 99.3 to ~~purchase~~this upReport on Form 6-K shall be deemed to anbe ~~additional~~incorporated ~~1,312,500~~by ~~ordinary~~reference ~~shares)~~into (the ~~“Shares”)~~registration ~~and~~statements on Form F-3 (~~ii) pre~~Registration Number 333-~~funded~~273757, ~~warrants~~333-277705 ~~(the~~and ~~“Pre~~333-~~Funded~~278650) ~~Warrants”~~and Form S-8 (Registration Number 333-252897) toof ~~purchase~~Pharvaris upN.V. and to ~~500,000~~be ~~ordinary~~a ~~shares~~part inthereof anfrom ~~underwritten~~the ~~offering~~date (on which this report is filed, to the ~~“Offering”).~~extent ~~The~~not ~~Offering~~superseded ~~closed~~by ondocuments ~~July 24,~~or ~~2025.~~reports subsequently filed or furnished.

~~The~~EXHIBIT Shares were sold in the Offering at the public offering price of $20.00 per share. The Pre-Funded Warrants were sold at a public offering price of $19.99 per Pre-Funded Warrant, which represents the per share public offering price for the ordinary shares less the $0.01 per share exercise price for each such Pre-Funded Warrant. Each Pre-Funded Warrant is exercisable as of July 24, 2025 until fully exercised, subject to an ownership limitation relating to the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, as set forth in the form of Pre-Funded Warrant. INDEX

The Offering was made pursuant to the Company’s effective registration statement on Form F-3ASR (Registration No. 333-278650), which was previously filed with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”) and became effective automatically upon filing.


Exhibit No.		Description
99.1		Press Release, dated August 12, 2025, (Financial results).
99.2		Management’s Discussion and Analysis of Financial Condition and Results of Operations as of and for the Three and Six Months Ended June 30, 2025 and 2024.
99.3		Unaudited Condensed Consolidated Interim Financial Statements as of and for the Three and Six Months Ended June 30, 2025 and 2024 and as of December 31, 2024.

The net proceeds from the Offering, after deducting the underwriting discounts and commissions, are expected to be approximately $201 million. The Company currently intends to use the net proceeds from the offering primarily to fund research and development expenses for its late-stage clinical programs, the hiring of a sales and marketing team in the U.S. and related commercialization expenses and for working capital and general corporate purposes. SIGNATURES

Pursuant to the ~~Underwriting~~requirements ~~Agreement,~~of the ~~Company’s~~Securities ~~executive~~Exchange ~~officers~~Act ~~and~~of ~~directors~~1934, ~~entered~~the ~~into~~registrant ~~agreements~~has induly ~~substantially~~caused ~~the~~this ~~form~~report ~~included as an exhibit~~ to ~~the~~be ~~Underwriting~~signed ~~Agreement,~~on ~~providing~~its ~~for~~behalf aby ~~90-day “lock-up” period with respect to sales of~~ the ~~Company’s ordinary shares~~undersigned, ~~subject~~thereunto toduly ~~certain exceptions~~authorized.

The foregoing is a summary description of the Underwriting Agreement and is qualified in its entirety by the text of the Underwriting Agreement filed as Exhibit 1.1 to this Current Report on Form 6-K and incorporated herein by reference.


	PHARVARIS N.V.

Date: August 12, 2025	By:	/s/ Berndt Modig
	Name:	Berndt Modig
	Title:	Chief Executive Officer

The form of Pre-Funded Warrant is filed as Exhibit 4.1 to this report and the foregoing description of the terms of the Pre-Funded Warrants is qualified in its entirety by reference to such exhibit.

A copy of the opinion of NautaDutilh N.V. relating to the validity of the Shares issued in the Offering is filed herewith as Exhibit 5.1. A copy of the opinion of Kirkland & Ellis LLP relating to the validity of the Pre-Funded Warrants issued in the Offering is filed herewith as Exhibit 5.2.

The Company hereby incorporates by reference the information contained in the body of this Report on Form 6-K into the Company’s Registration Statement on Form F-3ASR (File No. 333-278650), the Company’s Registration Statement on Form F-3 (File No. 333-273757), the Company’s Registration Statement on Form F-3ASR (File No. 333-277705 and the Company’s Registration Statement on Form S-8 (File No. 333-252897). This report on Form 6-K (including the exhibits filed herewith) is incorporated by reference into the Company’s Registration Statement on Form F-3ASR (File No. 333-278650).

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
1.1		Underwriting Agreement, dated July 22, 2025, among Pharvaris N.V., Morgan Stanley & Co. LLC, Leerink Partners LLC, Cantor Fitzgerald & Co., Oppenheimer & Co. Inc. and Van Lanschot Kempen (USA) Inc. as underwriters.
4.1		Form of Pre-Funded Warrant.
5.1		Opinion of NautaDutilh N.V.
5.2		Opinion of Kirkland & Ellis LLP.
23.1		Consent of NautaDutilh N.V. (contained in Exhibit 5.1).
23.2		Consent of Kirkland & Ellis LLP (contained in Exhibit 5.2).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PHARVARIS N.V.

Dated: July 24, 2025

/s/ Berndt Modig

Name: Berndt Modig

Title: Chief Executive Officer

Filing Compare · Pharvaris N.V.